IN8BIO, Inc.
INAB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001740279
No open-market purchases or sales by IN8BIO, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $5.35M in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding IN8BIO, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 17 | 22 | +5 |
| Shares | 1.37M | 2.33M | +963.0K (+70.5%) |
| Value | $1.78M | $3.59M | +$1.81M (+101.9%) |
New holders (7)
Institutions that held IN8BIO, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| State Street Corp | 59,246 | $91.2K | 0.00% |
| Citadel Advisors LLC | 57,722 | $88.9K | 0.00% |
| Overbrook Management Corp | 33,756 | $52.0K | 0.01% |
| Renaissance Technologies LLC | 21,700 | $33.0K | 0.00% |
| Two Sigma Investments, LP | 18,189 | $28.0K | 0.00% |
| Westside Investment Management, Inc. | 15,750 | $24.3K | 0.01% |
| Charles Schwab Investment Management Inc | 13,105 | $20.2K | 0.00% |
Sold out (2)
Institutions that held IN8BIO, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| UBS Group AG | 3,133 | $4.07K |
| Bank of America Corp | 38 | $50 |